Double or triple combination therapy in systemic arterial hypertension: to whom, when and with what?

Systemic arterial hypertension (SAH) is the main risk factor for premature death in the world and in Mexico. Around 15.2 million Mexicans have been estimated to be diagnosed with SAH, out of which 7.48 million are affiliated to IMSS (evaluation of the financial risks considered in the Institutional...

Full description

Saved in:
Bibliographic Details
Published inGaceta médica de México Vol. 156; no. 4
Main Authors Rosas-Peralta, Martín, Borrayo-Sánchez, Gabriela, Alcocer, Luis, Durán-Arenas, Juan L G, Borja-Aburto, Víctor H
Format Journal Article
LanguageEnglish
Published Mexico 14.05.2020
Online AccessGet full text

Cover

More Information
Summary:Systemic arterial hypertension (SAH) is the main risk factor for premature death in the world and in Mexico. Around 15.2 million Mexicans have been estimated to be diagnosed with SAH, out of which 7.48 million are affiliated to IMSS (evaluation of the financial risks considered in the Institutional Risk Management Program, ENSANUT, 2018). SAH is a complex, chronic disease that requires continuous medical attention with multifactorial risk reduction strategies, which go beyond numerical control in mm Hg of blood pressure and have been shown to be effective in reducing the vascular, cardiac and renal complications of the disease, as well as its impact on premature death. Continuous education and support in SAH self-management are essential to overcome the main challenges: treatment adherence and self-monitoring by the patient for the rest of his/her life.
ISSN:0016-3813